Details:

Corporate Authors:
Centers for Disease Control and Prevention (U.S.)
Description:
SUPPLEMENTARY TABLE. Demographic characteristics of v-safe respondents who received Janssen COVID-19 vaccine and completed at least one health survey during the 7 days after vaccination, March 2–April 12, 2021
Subject:
[+]
Ad26COVS1
Adolescent
Adult
Adverse Drug Reaction Reporting Systems
Aged
Aged, 80 And Over
Child
Child, Preschool
COVID-19 Vaccines/adverse Effects
Drug-Related Side Effects And Adverse Reactions
Drug Approval
Female
Humans
Infant
Infant, Newborn
Male
Middle Aged
Product Surveillance, Postmarketing
Risk Assessment
Safety-Based Drug Withdrawals
Sinus Thrombosis, Intracranial
Young Adult

Series:
MMWR. Morbidity and mortality supplementary materials
Document Type:
Table
Name as Subject:
Janssen COVID-19 Vaccine
Place as Subject:
United States
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:0a00aadca04a7fe1c59b35038a8c4256b943c06b58a23b1833be5a99a10004d3
File Type:

Supporting Files

• No Additional Files

More +